Royal Bank Of Canada Magenta Therapeutics, Inc. Transaction History

Royal Bank Of Canada

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$0.62 - $0.79 $292 - $372	471 Added 8.77%	5,843 $4,000
Q4 2022 Feb 14, 2023	SELL	$0.36 - $1.59 $4 - $20	-13 Reduced 0.24%	5,372 $2,000
Q3 2022 Nov 14, 2022	BUY	$1.26 - $2.09 $1,339 - $2,221	1,063 Added 24.6%	5,385 $8,000
Q2 2022 Aug 15, 2022	SELL	$0.97 - $3.08 $1,540 - $4,891	-1,588 Reduced 26.87%	4,322 $5,000
Q1 2022 May 16, 2022	SELL	$2.55 - $5.23 $12,920 - $26,500	-5,067 Reduced 46.16%	5,910 $17,000
Q4 2021 Feb 14, 2022	BUY	$4.43 - $8.33 $19,075 - $35,868	4,306 Added 64.55%	10,977 $48,000
Q3 2021 Nov 15, 2021	BUY	$6.07 - $9.89 $2,682 - $4,371	442 Added 7.1%	6,671 $49,000
Q2 2021 Aug 16, 2021	BUY	$9.76 - $14.15 $60,795 - $88,140	6,229 New	6,229 $61,000

442K

Ticker MGTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,890,500
Description
Magenta Therapeutics, Inc., a clinical-stage biotechnology company, develops medicines to bring the curative power of stem cell transplants to patients with blood cancers, genetic diseases, and autoimmune diseases. It develops MGTA-117, an anti-CD117 antibody that targets hematopoietic stem cells (HSCs) and genetically mutated stem cells that ca...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.